Primary small intestinal malignant tumors: survival analysis of 48 postoperative patients.
BACKGROUND
Primary small intestinal malignant tumor is relatively uncommon compared to gastric and colorectal cancer. It is difficult to make an early diagnosis due to the atypical primary symptoms and lack of effective diagnostic methods.


OBJECTIVE
To analyze the relationship between the prognoses, histologic type, and therapeutic strategy in postoperative patients with small intestinal tumor.


METHODS
The parameters that affect survival were evaluated using multivariate Cox analysis in 48 cases of small intestinal tumor (confirmed by operation and pathology) for the past 10 years.


RESULTS
The overall survival (OS) of all 48 cases after surgery was 28 months. The 5-year postoperative survival rate for all of the 48 cases was 27.1%. The median OS for all the 20 stage II/III patients who received adjuvant chemotherapy was 28 months, whereas the median OS for the 15 patients who did not receive the therapy was 37 months (P=0.276). The median time to progression for 8 patients with adenocarcinoma who received 5-fluorouracil or platinum-based palliative chemotherapy was 7 months, whereas for the patients who did not receive the therapy it was 3 months (P=0.06). The result of multivariate analyses showed that only the clinical stage was significantly correlated with OS (P<0.001).


CONCLUSIONS
The prognosis for small intestinal malignancies is associated with clinical stage, and palliative chemotherapy with a 5-fluorouracil or platinum-based regimen offers a potential benefit to patients with adenocarcinoma. Postoperative adjuvant chemotherapy seems to hold no therapeutic or survival benefit for patients with primary small bowel malignancies.
Cao
Jun
J
Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai Medical School, Shanghai 200032, P.R. China.
Zuo
Yunxia
Y
Lv
Fangfang
F
Chen
Zhiyu
Z
Li
Jin
J
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D007421:Intestine, Small / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010984:Platinum / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis
D000964:Antimetabolites, Antineoplastic; D010984:Platinum; D005472:Fluorouracil